Top Page
Radiopharm Theranostics Limited Sponsored ADR
(NASDAQ:RADX)
Radiopharm Theranostics Limited Sponsored ADR (RADX) vs. SPDR S&P 500 ETF (SPY)
Radiopharm Theranostics Limited Sponsored ADR Business Overview & Revenue Model
Radiopharm Theranostics Limited Sponsored ADR Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 3.63M | 299.23K | 292.36K | 8.83K |
| Gross Profit | 39.28K | 299.23K | 292.36K | 8.83K |
| EBITDA | -38.17M | -44.08M | -31.19M | -17.96M |
| Net Income | -38.34M | -47.95M | -34.61M | -30.34M |
Balance Sheet | ||||
| Total Assets | 86.48M | 72.04M | 74.95M | 83.38M |
| Cash, Cash Equivalents and Short-Term Investments | 29.12M | 18.58M | 11.70M | 26.98M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 43.61M | 44.68M | 29.37M | 20.42M |
| Stockholders Equity | 44.79M | 28.12M | 44.38M | 62.96M |
Cash Flow | ||||
| Free Cash Flow | -36.65M | -22.98M | -24.73M | -38.25M |
| Operating Cash Flow | -36.65M | -22.98M | -23.20M | -9.92M |
| Investing Cash Flow | 1.77M | -320.00K | -1.53M | -28.37M |
| Financing Cash Flow | 45.43M | 30.20M | 9.22M | 65.11M |
Radiopharm Theranostics Limited Sponsored ADR Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $57.75M | -0.88 | -50.23% | ― | ― | 21.17% | |
47 Neutral | $59.33M | -1.48 | -98.81% | ― | ― | ― | |
44 Neutral | $38.35M | -0.39 | ― | ― | -15.81% | -113.06% | |
44 Neutral | $30.82M | -0.39 | -62.30% | ― | -100.00% | -26.30% | |
42 Neutral | $28.47M | -0.45 | ― | ― | ― | ― |
Radiopharm Theranostics Limited Sponsored ADR Corporate Events
On 12 January 2026, Radiopharm Theranostics announced it had increased its ownership stake in Radiopharm Ventures, LLC, its radiopharmaceutical joint venture with The University of Texas MD Anderson Cancer Center, from 75% to 87.5%, signalling heightened confidence in the venture’s oncology pipeline. The move follows U.S. FDA IND clearance in July 2025 for Betabart (RV01), a B7H3‑targeting monoclonal antibody radiolabelled with lutetium-177, which is set to enter a Phase I dose-escalation therapeutic trial in multiple solid tumors with first patient dosing expected in the first quarter of 2026, in what is described as the first global clinical trial targeting B7H3 with a systemic radiopharmaceutical; alongside Betabart, two additional preclinical assets within Radiopharm Ventures have shown early positive data and are advancing toward final candidate selection in 2026, potentially strengthening Radiopharm’s position in the competitive cancer radiopharmaceuticals market and offering new avenues for growth for shareholders and partners.
The most recent analyst rating on (RADX) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited Sponsored ADR stock, see the RADX Stock Forecast page.
On December 3, 2025, Radiopharm Theranostics Limited announced the successful outcome of its General Meeting, where all proposed resolutions were approved by poll. The resolutions included the ratification of prior issue of shares and the approval of new share issuances and options, indicating strong shareholder support and potentially enhancing the company’s capital structure. This development could positively impact the company’s strategic initiatives and market positioning, reinforcing its commitment to advancing its radiopharmaceutical projects.
The most recent analyst rating on (RADX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited Sponsored ADR stock, see the RADX Stock Forecast page.
Radiopharm Theranostics Limited announced an Extraordinary General Meeting scheduled for December 3, 2025, to discuss several key resolutions, including the ratification of prior issued shares and approval for new share issuances. These resolutions, if passed, could significantly impact the company’s capital structure and provide additional resources for its ongoing projects. The meeting will be held both in person and virtually, allowing shareholders to participate and vote on these critical decisions.
The most recent analyst rating on (RADX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited Sponsored ADR stock, see the RADX Stock Forecast page.
Radiopharm Theranostics Limited announced its upcoming Annual General Meeting (AGM) scheduled for November 20, 2025, which will be held both physically in Victoria, Australia, and virtually via the Automic Investor Portal. The meeting will cover ordinary business such as the consideration of financial statements, re-election of directors, and the ratification of prior share placements. The AGM will also address special business, including the approval of equity securities issuance under the Omnibus Incentive Plan. This meeting is significant for stakeholders as it involves key decisions on corporate governance and strategic financial moves, potentially impacting the company’s future growth and shareholder value.
The most recent analyst rating on (RADX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited Sponsored ADR stock, see the RADX Stock Forecast page.